Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
2015年6月1日 更新者:Boehringer Ingelheim
Observational Study Assessing the Safety, Efficacy and Treatment Adherence of Nevirapine Extended Release (Combined With Other Antiretroviral Drugs) in HIV Infected Patients in Daily Clinical Practice
This Post Marketing Surveillance study will be performed as an open-label, prospective, non-interventional, uncontrolled study in Human immunodeficit Virus-1 (HIV-1) infected patients.
Data will only be documented in patients for whom a pharmacotherapy with nevirapine extended release is initiated.
Both anti-retroviral therapy (ART) naïve patients and pre-treated patients switching from nevirapine immediate release or other anti-retroviral therapy (ART) will be included in the study.
The decision to initiate treatment with nevirapine extended release is independent of this study and is based entirely on individual patient need and the judgement of the treating physician.
The aim of the study is to assess the safety and efficacy and treatment adherence of nevirapine extended release in HIV-1 infected patients in routine clinical practice.
It is planned to document five visits for each patient over a twenty four week observational period.
研究概览
地位
完全的
条件
详细说明
Study Design:
non-interventional uncontrolled observational study
研究类型
观察性的
注册 (实际的)
398
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
-
Graz、奥地利
- Boehringer Ingelheim Investigational Site 6
-
Salzburg、奥地利
- Boehringer Ingelheim Investigational Site 5
-
Vienna、奥地利
- Boehringer Ingelheim Investigational Site 1
-
Vienna、奥地利
- Boehringer Ingelheim Investigational Site 2
-
Vienna、奥地利
- Boehringer Ingelheim Investigational Site 3
-
Wels、奥地利
- Boehringer Ingelheim Investigational Site 4
-
-
-
-
-
Bialystok、波兰
- Boehringer Ingelheim Investigational Site 8
-
Bialystok、波兰
- Boehringer Ingelheim Investigational Site 7
-
Bydgoszcz、波兰
- Boehringer Ingelheim Investigational Site 9
-
Bydgoszcz、波兰
- Boehringer Ingelheim Investigational Site 10
-
Chorzów、波兰
- Boehringer Ingelheim Investigational Site 11
-
Chorzów、波兰
- Boehringer Ingelheim Investigational Site 12
-
Gdañsk、波兰
- Boehringer Ingelheim Investigational Site 13
-
Gdañsk、波兰
- Boehringer Ingelheim Investigational Site 14
-
Gdañsk、波兰
- Boehringer Ingelheim Investigational Site 15
-
Kraków、波兰
- Boehringer Ingelheim Investigational Site 16
-
Kraków、波兰
- Boehringer Ingelheim Investigational Site 17
-
Poznañ、波兰
- Boehringer Ingelheim Investigational Site 18
-
Wroc£aw、波兰
- Boehringer Ingelheim Investigational Site 19
-
Wroc£aw、波兰
- Boehringer Ingelheim Investigational Site 20
-
-
-
-
-
Bacau、罗马尼亚
- Boehringer Ingelheim Investigational Site 50
-
Brasov、罗马尼亚
- Boehringer Ingelheim Investigational Site 51
-
Brasov、罗马尼亚
- Boehringer Ingelheim Investigational Site 52
-
Brasov、罗马尼亚
- Boehringer Ingelheim Investigational Site 53
-
Bucuresti、罗马尼亚
- Boehringer Ingelheim Investigational Site 21
-
Bucuresti、罗马尼亚
- Boehringer Ingelheim Investigational Site 22
-
Bucuresti、罗马尼亚
- Boehringer Ingelheim Investigational Site 23
-
Bucuresti、罗马尼亚
- Boehringer Ingelheim Investigational Site 24
-
Bucuresti、罗马尼亚
- Boehringer Ingelheim Investigational Site 25
-
Bucuresti、罗马尼亚
- Boehringer Ingelheim Investigational Site 26
-
Bucuresti、罗马尼亚
- Boehringer Ingelheim Investigational Site 27
-
Bucuresti、罗马尼亚
- Boehringer Ingelheim Investigational Site 28
-
Bucuresti、罗马尼亚
- Boehringer Ingelheim Investigational Site 29
-
Bucuresti、罗马尼亚
- Boehringer Ingelheim Investigational Site 30
-
Bucuresti、罗马尼亚
- Boehringer Ingelheim Investigational Site 31
-
Bucuresti、罗马尼亚
- Boehringer Ingelheim Investigational Site 32
-
Bucuresti、罗马尼亚
- Boehringer Ingelheim Investigational Site 33
-
Bucuresti、罗马尼亚
- Boehringer Ingelheim Investigational Site 34
-
Bucuresti、罗马尼亚
- Boehringer Ingelheim Investigational Site 35
-
Bucuresti、罗马尼亚
- Boehringer Ingelheim Investigational Site 36
-
Bucuresti、罗马尼亚
- Boehringer Ingelheim Investigational Site 37
-
Bucuresti、罗马尼亚
- Boehringer Ingelheim Investigational Site 38
-
Bucuresti、罗马尼亚
- Boehringer Ingelheim Investigational Site 39
-
Bucuresti、罗马尼亚
- Boehringer Ingelheim Investigational Site 40
-
Bucuresti、罗马尼亚
- Boehringer Ingelheim Investigational Site 41
-
Bucuresti、罗马尼亚
- Boehringer Ingelheim Investigational Site 42
-
Bucuresti、罗马尼亚
- Boehringer Ingelheim Investigational Site 43
-
Bucuresti、罗马尼亚
- Boehringer Ingelheim Investigational Site 44
-
Constanta、罗马尼亚
- Boehringer Ingelheim Investigational Site 46
-
Constanta、罗马尼亚
- Boehringer Ingelheim Investigational Site 47
-
Constanta、罗马尼亚
- Boehringer Ingelheim Investigational Site 48
-
Giurgiu、罗马尼亚
- Boehringer Ingelheim Investigational Site 45
-
Ploiesti、罗马尼亚
- Boehringer Ingelheim Investigational Site 49
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 64年 (成人)
接受健康志愿者
不
有资格学习的性别
全部
取样方法
概率样本
研究人群
HIV-1 infected patients
描述
Inclusion criteria:
- HIV-1 infected male and female 18 years and above;
- anti-retroviral therapy (ART) naive and pre-treated patients switching from a nevirapine immediate release or other ART.
Exclusion criteria:
Consistent with the current VIRAMUNE prolonged release SPC.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
|---|
|
nevirapine extended release
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Patients Reporting Non-serious Adverse Events, Serious Adverse Events, and Non-serious and Serious Adverse Events Leading to Treatment Discontinuation
大体时间:up to 72 weeks
|
The primary endpoint is to evaluate the safety of a highly active antiretroviral therapy (HAART) that includes nevirapine extended release in routine clinical practice which is to assess the number of patients reporting non-serious adverse events (nSAEs), the number of patients with serious adverse events (SAE), the number of patients with non-serious adverse events leading to treatment discontinuation, and the number of patients with serious adverse events leading to discontinuation.
|
up to 72 weeks
|
|
Number of Patients Reporting Rash of Any Severity
大体时间:up to 72 weeks
|
Number of patients reporting rash of any severity as adverse event
|
up to 72 weeks
|
|
Number of Patients Reporting Hepatic Events
大体时间:up to 72 weeks
|
Number of patients reporting hepatic events either as adverse event (AE) or as laboratory abnormality of Grade 1 to Grade 4 in aspartate aminotransferase (AST), alanine transaminase (ALT), Gamma-Glutamyl-Transferase (Gamma-GT) and bilirubin.
|
up to 72 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Patients With Virologic Response at Week 24 (Viral Load <50 Copies/mL)
大体时间:24 weeks
|
Virologic response is defined as confirmed Human Immunodeficiency Virus (HIV) viral load of < 50 copies/mL (at two consecutive measurements after baseline) up to week 24 and without subsequent rebound or change of anti-retroviral (ARV) therapy up to week 24.
A rebound is defined as two consecutive measurements of viral load (VL) ≥ 50 copies/mL, at least two weeks apart, after two consecutive measurements of VL< 50 copies/mL.
A change of ARV therapy is defined as a permanent discontinuation of nevirapine extended release, addition of new ARV drugs, or alteration in background therapy.
A change in the background therapy due to toxicity or intolerance is not considered as treatment failure.
If no follow-up viral load was available the virologic response is Missing.
|
24 weeks
|
|
Change in CD4+ Cell Count From Baseline to Week 24
大体时间:baseline and week 24
|
The change in the Cluster of differentiation 4 (CD4+) cell count from baseline after 24 weeks was calculated by subtracting the baseline value from the value after 24 weeks.
Therefore, a positive change represents an increase in CD4+ cell count.
|
baseline and week 24
|
|
Change in Morisky Medication Adherence Scale Score From Baseline to 24 Weeks
大体时间:baseline and week 24
|
The Morisky Medication Adherence scale (MMAS-8 scale) is a recognized indicator of medication adherence, consisting of 8 questions with a sum score ranging between 0 and 8 points.
The higher score indicates higher adherence to the prescribed therapy recommendation.
It has been agreed that the score of 8 could be categorized as having high adherence, score between 6 and 7 as medium adherence and scores of 5 and less as low adherence.
The change is presented as the score after 24 weeks minus the score at baseline.
Therefore, a positive change score reflects an improvement in the adherence.
|
baseline and week 24
|
|
Number of Patients Reporting Once Daily Nevirapine Intake More Convenient Than Twice Daily Formulation
大体时间:24 weeks
|
The number of patients reporting that they find the once daily nevirapine intake more / very much more convenient than the twice daily formulation.
|
24 weeks
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
有用的网址
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2012年3月1日
初级完成 (实际的)
2014年5月1日
研究完成 (实际的)
2014年5月1日
研究注册日期
首次提交
2012年1月17日
首先提交符合 QC 标准的
2012年1月31日
首次发布 (估计)
2012年2月2日
研究记录更新
最后更新发布 (估计)
2015年6月2日
上次提交的符合 QC 标准的更新
2015年6月1日
最后验证
2015年6月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.